Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients

Methotrexate (MTX), a cytotoxic chemotherapeutic agent, is considered an effective drug in the treatment of psoriasis. The aim of this study was to find out whether the effect of MTX treatment in psoriasis is due to oxidative stress-induced apoptosis. Psoriasis vulgaris patients (58 in number) were...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental medicine 2014-11, Vol.14 (4), p.431-437
Main Authors: Elango, Tamilselvi, Dayalan, Haripriya, Gnanaraj, Pushpa, Malligarjunan, Hemamalini, Subramanian, Swapna
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antioxidants
Antioxidants - analysis
Apoptosis
Apoptosis - drug effects
Chemotherapy
Dermatologic Agents - therapeutic use
Female
Hematology
Humans
Internal Medicine
Male
Malondialdehyde - blood
Medicine
Medicine & Public Health
Methotrexate - therapeutic use
Middle Aged
Nitrates - blood
Nitrites - blood
Oncology
Original Article
Oxidative stress
Oxidative Stress - drug effects
Psoriasis
Psoriasis - drug therapy
Psoriasis - pathology
Reactive Oxygen Species - analysis
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Methotrexate (MTX), a cytotoxic chemotherapeutic agent, is considered an effective drug in the treatment of psoriasis. The aim of this study was to find out whether the effect of MTX treatment in psoriasis is due to oxidative stress-induced apoptosis. Psoriasis vulgaris patients (58 in number) were recruited for this study. Healthy volunteers (45 in number) served as control. Samples of psoriatic patients were collected and analyzed for total reactive oxygen species (ROS), malondialdehyde (MDA) levels, nitrite, nitrate levels and the activities of antioxidants like superoxide dismutase (SOD), catalase (CAT) and total antioxidant status (TAS) and also the protein expression of caspase-3, before (Day 0) and after (at the end of 6 and 12 weeks) MTX treatment. Our results show a significant increase in tissue ROS and plasma MDA after MTX treatment when compared with before MTX treatment in psoriasis patients ( p  
ISSN:1591-8890
1591-9528
DOI:10.1007/s10238-013-0252-7